AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Research

NIH-Funded Study Finds Effect of PrEP on Bone Density is Reversible

nih logo

The slight loss in bone mineral density associated with HIV pre-exposure prophylaxis (PrEP) antiretroviral use is reversible in young adult patients who stop taking the drugs, according to findings presented by researchers today at the 23rd Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. PrEP is an HIV prevention strategy in which at-risk HIV-negative…

Half of black gay men and a quarter of Latino gay men projected to be diagnosed within their lifetime

CDC Logo

If current HIV diagnoses rates persist, about 1 in 2 black men who have sex with men (MSM) and 1 in 4 Latino MSM in the United States will be diagnosed with HIV during their lifetime, according to a new analysis by researchers at the Centers for Disease Control and Prevention (CDC). The study, presented…

Vaginal Ring Provides Partial Protection from HIV in Large Multinational Trial

Woman holding the dapivirine vaginal ring tested in the NIH-funded ASPIRE study.
Credit: International Partnership for Microbicides

NIH-Funded Study Finds Protective Effect Strongest in Women over Age 25 A ring that continuously releases an experimental antiretroviral drug in the vagina safely provided a modest level of protection against HIV infection in women, a large clinical trial in four sub-Saharan African countries has found. The ring reduced the risk of HIV infection by…

Scientific Advances in HIV and HCV To Be Examined Next Week at CROI 2016

croi2016logo

The 2016 Conference on Retroviruses and Opportunistic Infections (CROI) takes place next week in Boston, and AIDS.gov will be there. This annual scientific meeting brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related…

Califf, FDA top officials call for sweeping review of agency opioids policies

FDA

Editor’s Note: Reducing opioid misuse not only reduces deaths from overdose but is also key to reducing new HIV and viral hepatitis infections among persons who inject drugs. For more on the link between opioid misuse, HIV and viral hepatitis, see this CDC report. In response to the opioid abuse epidemic, today Dr. Robert Califf, the…

FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4

FDA

The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients. Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure….

Seizing the Opportunity to “End the Scourge of HIV/AIDS

Richard J. Wolitski, Ph.D., Acting Director, Office of HIV/AIDS and Infectious Disease Policy, HHS

“Right now, we’re on track to end the scourge of HIV/AIDS. That’s within our grasp.”—President Barack Obama The power of those words really struck me when I heard President Obama say them in his final State of the Union address last week. I’ve wanted to believe that this was possible for the 30 years I’ve been…

ICYMI – NIH’s Dr. Anthony Fauci Pens Op-Ed on Tools to End HIV/AIDS

Fauci

In case you missed it, last week Dr. Anthony Fauci shared an op-ed in The Washington Post: “No more excuses. We have the tools to end the HIV/AIDS pandemic.” Dr. Fauci, Director of the National Institute of Allergy and Infectious Diseases at NIH, observes, “[W]hy does this global pandemic continue to rage? It is not…